Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2020-12-10
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure
NCT02546583
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
NCT06995144
Preparatory Work for a Trial of Adjuncts to Diuretic Treatment in Patients Hospitalised With Heart Failure: Addressing Uncertainties and Building Consensus
NCT07281040
A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients
NCT00690521
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2
NCT05753059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Torsemide
Patients enrolled in the TRANSFORM-HF study randomized to Torsemide, or patients prescribed Torsemide at hospital discharge
No interventions assigned to this group
Furosemide
Patients enrolled in the TRANSFORM-HF study randomized to Furosemide, or patients prescribed Furosemide at hospital discharge
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to provide blood and urine sample at enrollment and follow-up
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Duke University
OTHER
George Mason University
OTHER
University of Maryland, Baltimore
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Inova Health Care Services
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lauren Cooper, MD, MHS
Role: PRINCIPAL_INVESTIGATOR
Northwell Health
Christopher deFilippi, MD
Role: PRINCIPAL_INVESTIGATOR
Inova Health Care Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University School of Medicine
New Haven, Connecticut, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Baltimore VA
Baltimore, Maryland, United States
University of Minnesota
Minneapolis, Minnesota, United States
Northwell Health
Manhasset, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Duke University Hospital
Durham, North Carolina, United States
Inova Health System
Falls Church, Virginia, United States
Sentara Norfolk
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.